Medics-Ade Ltd 13241379 false 2024-04-01 2025-03-31 2025-03-31 The principal activity of the company is Medical Activities Digita Accounts Production Advanced 6.30.9574.0 true 13241379 2024-04-01 2025-03-31 13241379 2025-03-31 13241379 bus:OrdinaryShareClass1 2025-03-31 13241379 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 13241379 core:OtherPropertyPlantEquipment 2025-03-31 13241379 bus:SmallEntities 2024-04-01 2025-03-31 13241379 bus:AuditExemptWithAccountantsReport 2024-04-01 2025-03-31 13241379 bus:FilletedAccounts 2024-04-01 2025-03-31 13241379 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 13241379 bus:RegisteredOffice 2024-04-01 2025-03-31 13241379 bus:CompanySecretaryDirector1 2024-04-01 2025-03-31 13241379 bus:OrdinaryShareClass1 2024-04-01 2025-03-31 13241379 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 13241379 bus:Agent1 2024-04-01 2025-03-31 13241379 core:OtherPropertyPlantEquipment 2024-04-01 2025-03-31 13241379 core:PlantMachinery 2024-04-01 2025-03-31 13241379 countries:England 2024-04-01 2025-03-31 13241379 2024-03-31 13241379 core:OtherPropertyPlantEquipment 2024-03-31 13241379 2023-04-01 2024-03-31 13241379 2024-03-31 13241379 bus:OrdinaryShareClass1 2024-03-31 13241379 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-31 13241379 core:OtherPropertyPlantEquipment 2024-03-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 13241379

Medics-Ade Ltd
Unaudited Filleted Abridged Financial Statements
for the Year Ended 31 March 2025

Medics-Ade Ltd

Contents

Company Information | 1
Abridged Balance Sheet | 2
Notes to the Unaudited Abridged Financial Statements | 3 to 5

Medics-Ade Ltd

Company Information

Director | Dr Olayinka Daniel Aderinto

Company secretary | Dr Olayinka Daniel Aderinto

Registered office | Charles Rippin & Turner Middlesex House 130 College Road Harrow Middlesex HA1 1BQ

Accountants | Charles Rippin & Turner Middlesex House 130 College Road Harrow Middlesex HA1 1BQ

Medics-Ade Ltd

(Registration number: 13241379)
Abridged Balance Sheet as at 31 March 2025

| Note | 2025 £ | 2024 £
Fixed assets |  |  |
Tangible assets | 4 | 33,890 | 44,367
Creditors: Amounts falling due within one year |  | (12,647) | (17,624)
Total assets less current liabilities |  | 21,243 | 26,743
Accruals and deferred income |  | (6,300) | (6,000)
Net assets |  | 14,943 | 20,743
Capital and reserves |  |  |
Called up share capital | 5 | 1 | 1
Retained earnings |  | 14,942 | 20,742
Shareholders' funds |  | 14,943 | 20,743

For the financial year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

• | The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
• | The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

All of the company’s members have consented to the preparation of an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 18 February 2026

......................................... Dr Olayinka Daniel Aderinto Company secretary and director

Medics-Ade Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 March 2025

1 | General information

The company is a private company limited by share capital, incorporated in England.

The address of its registered office is:
Charles Rippin & Turner
Middlesex House
130 College Road
Harrow
Middlesex
HA1 1BQ

These financial statements were authorised for issue by the director on 18 February 2026.

2 | Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These abridged financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.
The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class | Depreciation method and rate
Plant and machinery | 18% reducing balance method

Medics-Ade Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 March 2025

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.
Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.
Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.
Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

3 | Staff numbers

The average number of persons employed by the company (including the director) during the year, was 1 (2024 - 1).

Medics-Ade Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 March 2025

4 | Tangible assets

| Other tangible assets £ | Total £
Cost or valuation
At 1 April 2024 | 51,840 | 51,840
At 31 March 2025 | 51,840 | 51,840
Depreciation
At 1 April 2024 | 7,473 | 7,473
Charge for the year | 10,477 | 10,477
At 31 March 2025 | 17,950 | 17,950
Carrying amount
At 31 March 2025 | 33,890 | 33,890
At 31 March 2024 | 44,367 | 44,367

5 | Share capital

Allotted, called up and fully paid shares

| 2025 | 2024
| No. | £ | No. | £
Ordinary share of £1 each | 1 | 1 | 1 | 1